Landec Shifting Shipments, Says Some Revenue+Profit Planned for Q2 Recognized in Q3; Shift Does Not Affect FY13
Landec Corporation (Nasdaq: LNDC), a materials science company that develops and markets innovative and patented products for food and biomedical applications, today announced that certain customers of its wholly-owned biomaterials subsidiary, Lifecore Biomedical, Inc., have requested that shipments originally planned to be shipped in November be shipped in December, which will result in revenues and profits planned for the second quarter being recognized in the third quarter. Therefore, approximately $3.0 million of gross profit is being shifted from Landec's second fiscal quarter to Landec's third fiscal quarter.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.